This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking. This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.